FDA Inspection 1117577 — AbbVie Clinical Pharmacology Research Unit (ACPRU)
The FDA completed an inspection of AbbVie Clinical Pharmacology Research Unit (ACPRU) on January 10, 2020 in Grayslake, IL. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- January 10, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Grayslake, IL (United States)
Additional Details
Clinical BA/BE